摘要
To the Editor:Worldwide,lung cancer,particularly non-small cell lung cancer(NSCLC),is the leading cause of tumor-related death.Cost-effectiveness analysis show no economic benefits for advanced NSCLC patients over chemotherapy.[1]Furthermore,tests such as programmed cell death ligand 1(PD-L1)and tumor mutational burden(TMB)tests,evaluated via immunohistochemical methods and next-generation sequencing,respectively,are widely used for screening potential beneficiaries of immune checkpoint inhibitors(ICIs).However,these two methods have different predictive values,making their comprehensive evaluation the focus of the current controversy.
基金
the grants from the Nation Key Research and Development Program of China(No.2016YFC1303800)
the National Natural Science Foundation of China(No.81802487)
the China postdoctoral foundation project(No.2019M651217)
the Research on the method of medical data correlation analysis and platform construction(No.45119031C003)
the Youth Development Foundation of the First Hospital of Jilin university(No.JDYY92018028)。